81 results
8-K
EX-99.1
ICU
SeaStar Medical Holding Corp
14 May 24
SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update
4:05pm
that is evaluating the safety and efficacy of our Selective Cytopheretic Device Adult (SCD-ADULT) in the significantly larger U.S. adult AKI patient population … with clinical results showing safety and probable clinical benefit to critically ill children with AKI who have few treatment options. The U.S. addressable
8-K
EX-99.1
ICU
SeaStar Medical Holding Corp
17 Apr 24
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
4:01pm
trial, which is evaluating the safety and efficacy of our Selective Cytopheretic Device (SCD) in the significantly larger adult AKI patient population … met the applicable criteria with clinical results showing safety and probable clinical benefit to critically ill children with AKI who have few
424B3
lyf dohezjh4
5 Mar 24
Prospectus supplement
5:08pm
424B3
h815mwzkcn
5 Mar 24
Prospectus supplement
5:06pm
424B3
v71peaxya
5 Mar 24
Prospectus supplement
4:59pm
424B3
tgn 1fdya15ba0fn1
5 Mar 24
Prospectus supplement
4:57pm
8-K
EX-99.1
j7h1l9 6ane9ju
22 Feb 24
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury
8:00am
8-K
EX-10.1
g56 ybtz8j741fwiw6
30 Jan 24
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
9:18am
8-K
EX-99.1
nn3u51dmy3u
21 Nov 23
SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update
6:04pm
424B3
as9stoynk5ftrbhj5
6 Oct 23
Prospectus supplement
1:08pm
424B3
6tnvd tegtqlix
6 Oct 23
Prospectus supplement
1:06pm
424B3
hygejv 11dgd5c01q6
6 Oct 23
Prospectus supplement
1:04pm
424B3
7iiepacxhatd5ezs5ylf
6 Oct 23
Prospectus supplement
12:59pm
8-K
EX-99.1
hxze2n
3 Oct 23
Company to finalize labeling with FDA Approvable Letter expected within a month
4:07pm